Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of different endurance exercise modalities on migraine days and cerebrovascular health in episodic migraineurs: A randomized controlled trial.
Hanssen H, Minghetti A, Magon S, Rossmeissl A, Rasenack M, Papadopoulou A, Klenk C, Faude O, Zahner L, Sprenger T, Donath L. Hanssen H, et al. Among authors: rasenack m. Scand J Med Sci Sports. 2018 Mar;28(3):1103-1112. doi: 10.1111/sms.13023. Epub 2018 Jan 8. Scand J Med Sci Sports. 2018. PMID: 29161767 Clinical Trial.
Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.
Naegelin Y, Rasenack M, Andelova M, Von Felten S, Fischer-Barnicol B, Amann M, Mehling M, Kappos L, Sprenger T, Derfuss T. Naegelin Y, et al. Among authors: rasenack m. Mult Scler Relat Disord. 2018 Oct;25:14-20. doi: 10.1016/j.msard.2018.07.005. Epub 2018 Jul 6. Mult Scler Relat Disord. 2018. PMID: 30014876 Free article.
Efficacy and Safety of Fingolimod in an Unselected Patient Population.
Rasenack M, Rychen J, Andelova M, Naegelin Y, Stippich C, Kappos L, Lindberg RL, Sprenger T, Derfuss T. Rasenack M, et al. PLoS One. 2016 Jan 6;11(1):e0146190. doi: 10.1371/journal.pone.0146190. eCollection 2016. PLoS One. 2016. PMID: 26734938 Free PMC article.
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH. Derfuss T, et al. Among authors: rasenack m. Mult Scler. 2015 Jun;21(7):885-93. doi: 10.1177/1352458514554052. Epub 2014 Nov 12. Mult Scler. 2015. PMID: 25392325 Clinical Trial.
Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.
Meira M, Sievers C, Hoffmann F, Haghikia A, Rasenack M, Décard BF, Kuhle J, Derfuss T, Kappos L, Lindberg RL. Meira M, et al. Among authors: rasenack m. Neurol Neuroimmunol Neuroinflamm. 2016 Mar 31;3(3):e223. doi: 10.1212/NXI.0000000000000223. eCollection 2016 Jun. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 27088119 Free PMC article.
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up.
Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH. Derfuss T, et al. Among authors: rasenack m. J Neuroimmunol. 2015 Aug 15;285:68-70. doi: 10.1016/j.jneuroim.2015.05.019. Epub 2015 May 20. J Neuroimmunol. 2015. PMID: 26198921 Clinical Trial.
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.
Zimmermann M, Sanderson NS, Rasenack M, Lalive PH, Lang AB, Curtin F, Lindberg RL, Kappos L, Derfuss T. Zimmermann M, et al. Among authors: rasenack m. Neurol Neuroimmunol Neuroinflamm. 2015 Aug 20;2(5):e144. doi: 10.1212/NXI.0000000000000144. eCollection 2015 Oct. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 26380353 Free PMC article.
20 results